AndreaBozzo/ceres-open-data-index huggingface dataset:
MD iMAP: Maryland Vital Statistics - Infant Deaths 2012

This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. Each Maryland County's number of infant deaths and infant mortality rates by race in 2012 and 2013. Includes: a) Number of Infant Deaths of All Races -  2012 -  b) Number of Infant Deaths of All Races -  2013 -  c) Infant Mortality Rate of All Races Per 1 - 000 Live Births -  2012 -  d) Infant Mortality Rate of All Races Per 1 - 000 Live Births -  2013 -  e) White Infant Deaths -  2012 -  f) White Infant Deaths -  2013 -  g) White Infant Mortality Rate Per 1 - 000 Live Births 2012 -  h) White Infant Mortality Rate Per 1 - 000 Live Births 2013 -  i) Black Infant Deaths -  2012 -  j) Black Infant Deaths -  2013 -  k) Black Infant Mortality Rate Per 1 - 000 Live Births 2012 -  l) Black Infant Mortality Rate Per 1 - 000 Live Births 2013 -  m) Number of Infant Deaths All Races from 2004-2008 -  n) Number of Infant Deaths All Races from 2009-2013 -  o) Average Infant Mortality Rate of All Races from 2004-2008 -  p) Average Infant Mortality Rate of All Races from 2009-2013 -  q) Percent Change of Infant Deaths.  Values = Rates based on <5 deaths are not presented since rates based on small numbers are statistically unreliable. Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_VitalStatistics/FeatureServer/2 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Compound 528367: 1-(2-(Pyridin-3-yl)pyrrolidin-1-yl)ethanone

Chemical compound data from PubChem database. IUPAC Name: 1-(2-pyridin-3-ylpyrrolidin-1-yl)ethanone. Molecular Formula: C11H14N2O. Molecular Weight: 190.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The Kinship Navigator Program

The Family First Prevention Services Act enacted as part of Public Law (PL) 115 -123, amended Title IV-E to allow title IV-E agencies the option to receive funding for evidence-based kinship navigator programs that meet certain criteria.  Kinship navigator programs help relative and kin caregivers learn about and access programs and services to meet their own needs and the needs of the children they are raising.

Kinship Navigator Programs must meet the requirements described in section 427(a)(1) of the Social Security Act, as follows:

Title IV-E agencies approved to operate the program may claim 50 percent Federal Financial Participation (FFP) for allowable kinship navigator programs.  Title IV-E Kinship Navigator Program requires use of program models that have been reviewed and rated by the Title IV-E Prevention Services Clearinghouse
  
  

 as meeting promising, supported, or well-supported practice standards.

To apply to participate in the program, title IV-E agencies must submit an attachment to their title IV-E plan, following guidance provided in Program Instruction ACYF-CB-PI-18-11.

As of August 2025, there are 12 title IV-E agencies approved to operate an evidence-based kinship navigator program: Colorado, Ohio, Iowa, Minnesota, Nebraska, Nevada, Puerto Rico, South Carolina, Utah, Virginia, Washington.  (Delaware’s plan is being reviewed).

Title IV-E Agency

Title IV-E Kinship Navigator Program Implemented

Metadata-only record linking to the original dataset. Open original dataset below.
HIV/AIDS Cases

This data set includes tables on persons living with HIV/AIDS, newly diagnosed HIV cases and all cause deaths in HIV/AIDS cases by gender, age, race/ethnicity and transmission category.

In all tables, cases are reported as of December 31 of the given year, as reported by January 9, 2019, to allow a minimum of 12 months reporting delay.

Gender is determined by both current gender and sex at birth variables; transgender values are assigned when current gender is identified as "Transgender" or when a discrepancy is identified between a person's sex at birth and their current gender (e.g., cases where sex at birth is "Male" and current gender is "Female" will become Transgender: Male to Female.) Prior to 2003, Asian and Native Hawaiian/Pacific Islanders were classified as one combined group. In order to present these race/ethnicities separately, living cases recorded under this combined classification were split and redistributed according to their expected proportional population representation estimated from post-2003 data.
Healthy Chicago Equity Zones

Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health (CDPH) to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six Equity Zones, through which the City collaborates with regional and neighborhood organizations to address issues of common concern – like COVID-19 vaccine distribution, health care access, violence prevention, and food security – and improve quality of life at the neighborhood level.

The Equity Zones are the following.

Far South: Beverly, Burnside, Calumet Heights, East Side, Hegewisch, Morgan Park, Mount Greenwood, Pullman, Riverdale, Roseland, South Deering, Washington Heights, West Pullman

Near South: Auburn Gresham, Avalon Park, Chatham, Douglas, Englewood, Fuller Park, Grand Boulevard, Greater Grand Crossing, Hyde Park, Kenwood, Oakland, South Chicago, South Shore, Washington Park, West Englewood, Woodlawn

North/Central: Edgewater, Lake View, Lincoln Park, Lincoln Square, Loop, Near North Side, Near South Side, North Center, Rogers Park, Uptown, West Ridge

Northwest: Albany Park, Avondale, Belmont Cragin, Dunning, Edison Park, Forest Glen, Hermosa, Irving Park, Jefferson Park, Logan Square, Montclare, North Park, Norwood Park, O'Hare, Portage Park

Southwest: Archer Heights, Armour Square, Ashburn, Bridgeport, Brighton Park, Chicago Lawn, Clearing, Gage Park, Garfield Ridge, McKinley Park, New City, West Elsdon, West Lawn

West: Austin, East Garfield Park, Humboldt Park, North Lawndale, South Lawndale, Lower West Side, Near West Side, West Garfield Park, West Town

​​​​​This dataset is in a forma​​t for spatial datasets that is inherently tabular but allows for a map as a derived view. Please click the indicated link below for such a map.

To export the data in either tabular or geographic format, please use the Export button on this dataset.
Compound 528067: N,O,O-Tris(dimethyl-t-butylsilyl)-l-tyrosine

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[[tert-butyl(dimethyl)silyl]amino]-3-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]propanoate. Molecular Formula: C27H53NO3Si3. Molecular Weight: 524.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA DataNSDUH 2021 Highlighted Population Slides

Use these slides to explore substance use and mental health measures for particular populations in the United States. The slides are based on the 2021 National Survey on Drug Use and Health (NSDUH), which is administered to civilians 12 and older not living in institutions. Within each slide deck, selected estimates are presented overall, by age group, and for selected sub-populations. Slides for the following populations are available:American Indian and Alaska Natives (AIAN)AsiansBlack or African AmericansFemalesHispanics or LatinosMultiracial PeopleNative Hawaiians and Other Pacific Islanders (NHOPI)VeteransThe slides are available as PDF or PowerPoint files.
Patent AT-E399653-T1: [Translated] DEVICE FOR FILLING SHEETS INTO AN ENVELOPE

The invention relates to a device for inserting sheets into an envelope, comprising a holding device (11) for holding the envelope, transport means (15) for feeding the sheets to be inserted to the holding device (11), a feed device (7, 8, 9) for feeding the envelope to the holding device (11), along a feed direction, and a removal device (8, 22) for removing the filled envelope from the holding device (11), along a removal direction. The invention is characterized in that the feed device (7, 8, 9) and the removal device (8, 22) are disposed relative to the holding device (11) in such a manner that a first angle between the feed device and a main surface of the holding device (11) and a second angle between the removal direction and the main surface of the holding device (11) are predetermined in a fixed manner and are different from each other. The invention allows to simplify the construction of the device, thereby reducing its technical complexity and failure proneness. The elimination of a swiveling movement results in a gain in time, thereby increasing the capacity of the device.
2012 Uniform Reporting System (URS) Tables for Indiana

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Quality Assurance Reporting Requirements (QARR) Health Disparities 2024

This dataset includes Medicaid Managed Care, Commercial HMO, and Commercial PPO performance data from the Quality Assurance Reporting Requirements (QARR) by member demographic characteristics. QARR is largely based on measures of quality developed and published by the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®). Plans are required to submit quality performance data each year. Demographic information analyzed in this report includes members’ sex, age, race/ethnicity, Medicaid aid category, cash assistance status, behavioral health conditions including serious mental illness (SMI) and substance use disorder (SUD), payer status, and region of residence. Measuring the quality of care, and the ability to measure disparities in care is an important first step to a better understanding of the underlying factors that drive differences in care among certain populations within Medicaid Managed Care, Commercial HMO, and Commercial PPO.

The data is published annually for the Medicaid Managed Care Reports for Quality Performance: Health Care Disparities in New York State <a href=http://www.health.ny.gov/health_care/managed_care/reports/>http://www.health.ny.gov/health_care/managed_care/reports/</a>
Mississippi 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 526758: 11-Hexyl-oxacycloundecan-2-one

Chemical compound data from PubChem database. IUPAC Name: 11-hexyl-oxacycloundecan-2-one. Molecular Formula: C16H30O2. Molecular Weight: 254.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose

Background
          A study for pain relief therapy with 188Re-HEDP was done in patients with bone metastases secondary to breast and prostate cancer.
        
        
          Materials and Methods
          Patients received 1.3 or 2.2 GBq, in single or multiple doses. Platelets, white and red cells were evaluated during 11 weeks. Pharmacokinetic characterization was done from blood and urine samples for 5 patients along 24 hours. Urinary excretion was evaluated in other 16 patients during 6 hours. Bone uptake was estimated as remaining activity in whole body. Scintigraphic images were acquired at 2 and 24 hs post-administration. Absorbed dose in bone marrow was estimated with Mirdose3. Analgesics intake and pain score were daily recorded. Tumour markers (PSA, and Tn-structure) were monitored in 9 patients during 4 to 6 months. Single doses of low activity (1.3 GBq) were given to twelve patients. Nine patients received multiple doses.
        
        
          Results
          All except one patient had normal levels of platelets, white and red cells. Remaining dose in blood at 2 hours was 9%. Urinary elimination was 58%. Bone uptake at 24 hours was 43% (mean value; n = 5). No changes of the haematological parameters were detected along follow-up period. Pain relief was evidenced by decrease or supression of opioid analgesic and by subjective index. PSA showed a decrease in prostate cancer patients (n = 4). Tn-structure showed a significant increase after 4 to 8 months.
        
        
          Conclusion
          Single or multiple dose scheme could be safely used, with administered activity of 188Re-HEDP up to 60 mCi, with low bone marrow absorbed doses.
Compound 527982: Pentanoic acid, 4-methyl-, 2-chloro-1-(chloromethyl)ethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1,3-dichloropropan-2-yl 4-methylpentanoate. Molecular Formula: C9H16Cl2O2. Molecular Weight: 227.12. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525777: 4-Butyl-2,5-dimethyloxazole

Chemical compound data from PubChem database. IUPAC Name: 4-butyl-2,5-dimethyl-1,3-oxazole. Molecular Formula: C9H15NO. Molecular Weight: 153.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525269: N'-(3-fluoro-phenyl)-N,N-dimethyl-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-fluorophenyl)-N,N-dimethylethanimidamide. Molecular Formula: C10H13FN2. Molecular Weight: 180.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529080: bis-[3,3-(2-Methylpropanol-1)] disulfide

Chemical compound data from PubChem database. IUPAC Name: 3-[(3-hydroxy-2-methylpropyl)disulfanyl]-2-methylpropan-1-ol. Molecular Formula: C8H18O2S2. Molecular Weight: 210.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Analysis of prolactin-modulated gene expression profiles during the Nb2 cell cycle using differential screening techniques

Background:
          Rat Nb2-11C lymphoma cells are dependent on prolactin for proliferation and are widely used to study prolactin signaling pathways. To investigate the role of this hormone in the transcriptional mechanisms that underlie prolactin-stimulated mitogenesis, five different techniques were used to isolate differentially expressed transcripts: mRNA differential display, representational difference analysis (RDA), subtractive suppressive hybridization (SSH), analysis of weakly expressed candidate genes, and differential screening of an organized library.
        
        
          Results:
          About 70 transcripts were found to be modulated in Nb2 cells following prolactin treatment. Of these, approximately 20 represent unknown genes. All cDNAs were characterized by northern blot analysis and categorized on the basis of their expression profiles and the functions of the known genes. We compared our data with other cell-cycle-regulated transcripts and found several new potential signaling molecules that may be involved in Nb2 cell growth. In addition, abnormalities in the expression patterns of several transcripts were detected in Nb2 cells, including the constitutive expression of the immediate-early gene EGR-1. Finally, we compared the differential screening techniques in terms of sensitivity, efficiency and occurrence of false positives.
        
        
          Conclusions:
          Using these techniques to determine which genes are differentially expressed in Nb2 lymphoma cells, we have obtained valuable insight into the potential functions of some of these genes in the cell cycle. Although this information is preliminary, comparison with other eukaryotic models of cell-cycle progression enables identification of expression abnormalities and proteins potentially involved in signal transduction, which could indicate new directions for research.
Compound 526737: 2-(2-nonyloxy-ethoxy)-ethanol, TFA

Chemical compound data from PubChem database. IUPAC Name: 2-(2-nonoxyethoxy)ethyl 2,2,2-trifluoroacetate. Molecular Formula: C15H27F3O4. Molecular Weight: 328.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Survey on Drug Use and Health (NSDUH-2007)

<p>The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2007 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.</p>
Compound 529820: Octanal, 2,4,6-trichlorophenyl hydrazone

Chemical compound data from PubChem database. IUPAC Name: 2,4,6-trichloro-N-(octylideneamino)aniline. Molecular Formula: C14H19Cl3N2. Molecular Weight: 321.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530209: Benzeneacetic acid, 3-methoxy-alpha-[(trimethylsilyl)oxy]-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(3-methoxyphenyl)-2-trimethylsilyloxyacetate. Molecular Formula: C15H26O4Si2. Molecular Weight: 326.53. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases

Background
          The autoimmune thyroid diseases (AITDs), comprising Graves' disease (GD) and Hashimoto's thyroiditis (HT), appear to develop as a result of complex interactions between predisposing genes and environmental triggers. Susceptibility to AITDs is conferred by genes in the human leukocyte antigen (HLA) and genes unlinked to HLA, including the CTLA-4 gene. Recently, an association to some estrogen receptor (ER)α genotypes with breast cancer, hypertension, osteoporosis, generalized osteoarthritis, and some autoimmune diseases such as rheumatoid arthritis has been reported. We have analyzed a dinucleotide (TA)n repeat polymorphism lying upstream of the human ERα gene in patients with AITDs and in normal subjects.
        
        
          Results
          Seventeen different alleles were found in 130 patients with GD, 93 patients with HT, and 190 control subjects. There was no significant difference in the distributions of ERα alleles between patients and controls.
        
        
          Conclusions
          The present results do not support an association between the ERα gene and AITD in the Japanese population.
Compound 530438: 4-Ethylbenzoic acid, 1-adamantylmethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1-adamantylmethyl 4-ethylbenzoate. Molecular Formula: C20H26O2. Molecular Weight: 298.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.